A preclinical biopharma company focused on making metastatic cancer cells more vulnerable to existing treatments has secured $880K in new capital. VIOLET Pharmaceuticals is developing a First-in-Class mRNA nanotherapy designed to directly modulate the Antigen Presentation Machinery (APM) in tumor cells, a mechanism currently unaddressed by specific therapies on the market.
This patented technology aims to improve the efficiency and expand the approved indications of immunotherapies, such as Immune Checkpoint Inhibitors. Backed by science published in leading journals, VIOLET's mRNA nanotherapy has demonstrated radical complete responses in breast cancer tumor and metastasis models when combined with these existing treatments.
